Form 4: Solid Biosciences CRO Hanrahan Reports Equity Changes

Solid Biosciences' Chief Regulatory Officer, Jessie Hanrahan, reported the vesting of performance and restricted stock units, new equity grants, and a tax-related share sale.

Summary

• Jessie Hanrahan, Chief Regulatory Officer of Solid Biosciences Inc. [SLDB], reported several equity transactions.
• On January 29, 2026, 54,925 common shares were acquired upon the vesting of Performance Stock Units (PSUs), following the achievement of a pre-determined performance milestone.
• On January 29, 2026, Hanrahan was granted 190,000 Employee Stock Options with an exercise price of $6.60, which will vest over four years.
• Also on January 29, 2026, 95,000 Restricted Stock Units (RSUs) were granted, which will vest over four years.
• On January 31, 2026, 27,625 common shares were acquired upon the vesting of previously granted RSUs from a January 31, 2025 grant.
• On February 2, 2026, 26,535 common shares were sold at a weighted average price of $6.4369 to cover withholding taxes related to the vesting of PSUs; this was not a discretionary trade.
• Following these transactions, Hanrahan directly owns 82,675 common shares, 190,000 employee stock options, and 177,875 restricted stock units (95,000 from the 2026 grant plus 82,875 remaining from the 2025 grant).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, reflecting the achievement of performance milestones and ongoing executive compensation, which aligns management incentives with company performance. The tax-related sale is a routine event.

Positives

• The vesting of 54,925 Performance Stock Units (PSUs) indicates the achievement of a pre-determined business objective, as certified by the Board.
• The grant of 190,000 Employee Stock Options and 95,000 Restricted Stock Units (RSUs) on January 29, 2026, represents ongoing compensation and aligns management interests with shareholders.
• The vesting of 27,625 Restricted Stock Units (RSUs) on January 31, 2026, further demonstrates the realization of equity compensation.

Negatives

• The sale of 26,535 common shares, although for tax withholding purposes, reduces the direct beneficial ownership of the Chief Regulatory Officer.

Future Outlook

The filing indicates future vesting events for the newly granted employee stock options and restricted stock units. The 190,000 employee stock options and 95,000 restricted stock units granted on January 29, 2026, will vest over four years, with 25% vesting on the first anniversary and monthly thereafter for options, and 25% annually for RSUs. The remaining 82,875 restricted stock units from the January 31, 2025 grant will also continue to vest annually until the fourth anniversary of that grant.

Management Comments

• "This sale was made to cover withholding taxes following the vesting of previously granted PSUs pursuant to a durable automatic sale instruction letter adopted by Dr. Hanrahan on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Hanrahan."

Industry Context

StockSavvy.ai notes that equity grants and vesting events are standard components of executive compensation packages in the biotechnology and pharmaceutical industries, aiming to align executive incentives with long-term company performance and shareholder value. The achievement of performance milestones for PSUs is a positive indicator of internal operational progress.

Comparison to Industry Standards

• StockSavvy.ai observes that the vesting schedule of 25% on the first anniversary and monthly thereafter for options, and 25% annually for RSUs over four years, is a common industry standard for executive equity compensation in the biotech sector, comparable to practices at companies like Sarepta Therapeutics or BioMarin Pharmaceutical, which use similar multi-year vesting schedules to retain talent and incentivize long-term performance.
• The 'sell-to-cover' mechanism for tax obligations upon vesting is also a widely adopted practice among executives across various industries, including technology and healthcare, to manage tax liabilities without requiring personal funds.

Stakeholder Impact

• Shareholders: The vesting of PSUs indicates the achievement of business objectives, which could be positive. The grants align executive interests with shareholder value. The sell-to-cover is a minor dilution event but expected.
• Employees: The equity grants are part of a compensation structure designed to attract and retain key personnel.

Next Steps

• Continued vesting of 190,000 Employee Stock Options, with 25% vesting on January 29, 2027, and monthly thereafter until January 29, 2030.
• Continued vesting of 95,000 Restricted Stock Units, with 25% vesting on each anniversary of January 29, 2026, until January 29, 2030.
• Continued vesting of the remaining 82,875 Restricted Stock Units from the January 31, 2025 grant, with annual vesting until January 31, 2029.

Key Dates

Keywords

Solid Biosciences, SLDB, Jessie Hanrahan, Form 4, insider trading, stock options, restricted stock units, performance stock units, equity compensation, beneficial ownership, sell-to-cover